Can enfortumab vedotin plus pembrolizumab improve event-free survival in muscle-invasive bladder cancer?
Join Jonathan Chatzkel, MD, at #ESMO26 tomorrow, where he shares exploratory analyses from the KEYNOTE-B15/EV-304 trial. #MoffittESMO26
421 views · 5 likes · 3 reposts · 0 replies
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.orgSource: Moffitt Cancer Center · x.com